Cargando…
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164720/ https://www.ncbi.nlm.nih.gov/pubmed/25228832 http://dx.doi.org/10.3904/kjim.2014.29.5.577 |
| _version_ | 1782334993489461248 |
|---|---|
| author | Kwok, Seung-Ki |
| author_facet | Kwok, Seung-Ki |
| author_sort | Kwok, Seung-Ki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4164720 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | The Korean Association of Internal Medicine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-41647202014-09-16 Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? Kwok, Seung-Ki Korean J Intern Med Editorial The Korean Association of Internal Medicine 2014-09 2014-08-28 /pmc/articles/PMC4164720/ /pubmed/25228832 http://dx.doi.org/10.3904/kjim.2014.29.5.577 Text en Copyright © 2014 The Korean Association of Internal Medicine http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Kwok, Seung-Ki Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title | Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title_full | Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title_fullStr | Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title_full_unstemmed | Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title_short | Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA? |
| title_sort | could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (ra) patients with insufficient response to methotrexate, be the breakthrough drug for ra? |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164720/ https://www.ncbi.nlm.nih.gov/pubmed/25228832 http://dx.doi.org/10.3904/kjim.2014.29.5.577 |
| work_keys_str_mv | AT kwokseungki couldtofacitinibthefirstoralsmallmoleculeinhibitorprovenforuseinactiverheumatoidarthritisrapatientswithinsufficientresponsetomethotrexatebethebreakthroughdrugforra |